Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has only been a few weeks since my previous article , where I covered the FDA blindsiding ImmunityBio ( IBRX ) with a Refusal to File (RTF) letter for ANKTIVA’s supplemental BLA in papillary-only NMIBC. The market reacted harshlyHe is the leader of th ...